ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA(r) (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole
November 18, 2015 11:50 ET
|
ThromboGenics NV
Importance of proper patient selection demonstrated
No new safety signals identified, majority of adverse events resolve
LEUVEN, Belgium, Nov. 18, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV...
ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA(r) for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)
November 12, 2015 01:35 ET
|
ThromboGenics NV
ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy...
ThromboGenics Starts Evaluating JETREA(r) for the Treatment of Retinal Vein Occlusion (RVO)
April 23, 2015 01:36 ET
|
ThromboGenics NV
LEUVEN, Belgium, April 23, 2015 (GLOBE NEWSWIRE) -- Company receives € 0.6 million research grant from IWT, the Flemish Agency for Innovation by Science and Technology
ThromboGenics NV...
ThromboGenics' JETREA(r) Gains Approval in Brazil
March 16, 2015 02:05 ET
|
ThromboGenics NV
LEUVEN, Belgium, March 16, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
ThromboGenics Receives Positive CHMP Opinion for Ready Diluted Formulation of JETREA(r)
March 02, 2015 11:55 ET
|
ThromboGenics NV
LEUVEN, Belgium, March 2, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
Thrombogenics Awarded EU1.1 million IWT Research Grant
February 05, 2015 02:06 ET
|
ThromboGenics NV
LEUVEN, Belgium, Feb. 5, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
ThromboGenics Appoints Emmanuele Attout as Independent Non-Executive Director
January 22, 2015 04:02 ET
|
ThromboGenics NV
LEUVEN, Belgium, Jan. 22, 2015 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
ThromboGenics' JETREA(R) Gains Approval in South Korea
September 08, 2014 01:54 ET
|
ThromboGenics NV
LEUVEN, Belgium, Sept. 8, 2014 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
ThromboGenics Activates 50th Retina Center for its US Observational Patient Trial with JETREA(R) (ORBIT)
April 29, 2014 01:40 ET
|
ThromboGenics NV
LEUVEN, Belgium, April 29, 2014 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...
ThromboGenics Announces Business Update and 2013 Full-Year Results
March 17, 2014 12:55 ET
|
ThromboGenics NV
REGULATED INFORMATION
JETREA ® in the US
US sales of JETREA® were €20.2 million in 2013, with close to 7000 patients treated
In the second half of 2013, the Company...